- Home
- ARMP vs ONCY Comparison
ARMP vs ONCY Comparison
Compare ARMP & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARMP
- ONCY
- Stock Information
- Founded
- ARMP N/A
- ONCY 1998
- Country
- ARMP United States
- ONCY Canada
- Employees
- ARMP N/A
- ONCY N/A
- Industry
- ARMP Biotechnology: Biological Products (No Diagnostic Substances)
- ONCY Pharmaceuticals and Biotechnology
- Sector
- ARMP Health Care
- ONCY Health Care
- Exchange
- ARMP Nasdaq
- ONCY Nasdaq
- Market Cap
- ARMP 92.4M
- ONCY 89.7M
- IPO Year
- ARMP N/A
- ONCY 1999
- Fundamental
- Price
- ARMP $2.86
- ONCY $1.24
- Analyst Decision
- ARMP Strong Buy
- ONCY Strong Buy
- Analyst Count
- ARMP 1
- ONCY 5
- Target Price
- ARMP $9.00
- ONCY $5.00
- AVG Volume (30 Days)
- ARMP 12.1K
- ONCY 1.2M
- Earning Date
- ARMP 11-12-2025
- ONCY 11-11-2025
- Dividend Yield
- ARMP N/A
- ONCY N/A
- EPS Growth
- ARMP N/A
- ONCY N/A
- EPS
- ARMP N/A
- ONCY N/A
- Revenue
- ARMP $6,868,000.00
- ONCY N/A
- Revenue This Year
- ARMP $8.43
- ONCY N/A
- Revenue Next Year
- ARMP N/A
- ONCY N/A
- P/E Ratio
- ARMP N/A
- ONCY N/A
- Revenue Growth
- ARMP 84.67
- ONCY N/A
- 52 Week Low
- ARMP $0.90
- ONCY $0.33
- 52 Week High
- ARMP $3.14
- ONCY $1.53
- Technical
- Relative Strength Index (RSI)
- ARMP 57.54
- ONCY 58.08
- Support Level
- ARMP $2.79
- ONCY $1.05
- Resistance Level
- ARMP $3.03
- ONCY $1.44
- Average True Range (ATR)
- ARMP 0.16
- ONCY 0.11
- MACD
- ARMP 0.01
- ONCY 0.02
- Stochastic Oscillator
- ARMP 62.16
- ONCY 59.18
About ARMP Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.
About ONCY Oncolytics Biotech Inc.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.